TFE3 and nonpapillary renal cell carcinoma: To our knowledge, this is the first study that compares TFE3-rearranged-RCC with ccRCC; survival analysis indicated that TFE3-rearranged RCC exhibited a significantly shorter progression-free survival, compared to ccRCC.